Abstract: A method of manufacturing 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)-malononitrile ([F-18]FDDNP) utilizes a semi-automated module that is used to perform fluorination, pre-purification, separation, product extraction, and formulation. The method is able to produce [F-18]FDDNP with high yields and ready for human administration under existing FDA regulations, and without the need for hazardous organic solvents such as dichloromethane (DCM), methanol (MeOH), and tetrahydrofuran (THF). The method also improves the speed with which [F-18]FDDNP can be synthesized with the method being able to generate a final product within about 90 to 100 minutes. This synthesis method is easily adaptable to FDA registered and approved automated synthesis systems.

Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. Furthermore, the present invention relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used for the treatment of Huntington's disease, Alzheimer's disease, Multiple Sclerosis, Lateral Sclerosis, Neural Motor disorders.

Abstract: The present disclosure relates to a sulfonated benzene compound emitting fluorescence by reaction with hydrogen peroxide, aqueous-dispersed fluorescent nanoprobes applicable for real-time detection of hydrogen peroxide, and a fluorescent nanoprobe fabrication method. The fluorescent nanoprobe contains the following sulfonated benzene compound and water.

Abstract: Acids, such as hydrochloric acid, are pumped down in to the formation in acidizing treatments of oil & gas wells, thru metal pipes/tubing. Corrosion Inhibition of these metal surfaces (pipes, tubing, etc) has been extensively studied. Most known acid corrosion inhibitors (ACI) and acid corrosion inhibitors currently used in the oilfield contain ingredients that are an environmental concern or have poor Health, Safety and Environmental (HSE) characteristics. This invention relates to the discovery of a Novel Acid Corrosion Inhibitor. Aromatic Nitriles, especially Cinnamyl Nitrile, when added to the acid in effective amounts, offers acceptable rates of corrosion inhibition. Cinnamyl Nitrile can be substituted in place of ingredients that have poor HSE characteristics, to improve the HSE characteristics of acid corrosion inhibitors, without sacrificing corrosion inhibition performance.

Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Abstract: Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds from an isomerically pure starting material are described. In particular, methods of preparing a 3-(1-(dimethylamino)-2-methylpentane-3-yl)phenol as a substantially optically pure (R,R) stereoisomer are described. Using a method of the present invention, only the (R,R) and (S,S) stereoisomers of the target compound are produced, increasing the yield and stereoselectivity of the desired (R,R) stereoisomer.

Abstract: Photoactive compositions of matter, methods for their design and synthesis, and various applications of such compositions of matter are disclosed. Such photoactive compositions may, for example, include any one or more of the following: a core moiety; a primary electron donor moiety; an electron-withdrawing moiety; and an alkyl tail. Some photoactive compositions may further include multiple additional electron donor moieties, electron-withdrawing moieties, and alkyl tails. Methods for designing such photoactive compositions may include selecting a core moiety; selecting an electron-withdrawing moiety to add to the core moiety in order to modify the composition's electronic properties; selecting a primary electron donor moiety to be added in order to further modify the composition's electronic properties; selecting a second electron donor moiety to be added in order to modify the composition's electronic properties even further, if necessary; and synthesizing the designed composition.

Abstract: Photoactive compositions of matter, methods for their design and synthesis, and various applications of such compositions of matter are disclosed. Such photoactive compositions may, for example, include any one or more of the following: a core moiety; a primary electron donor moiety; an electron-withdrawing moiety; and an alkyl tail. Some photoactive compositions may further include multiple additional electron donor moieties, electron-withdrawing moieties, and alkyl tails. Applications of such photoactive compositions of matter may include use in photovoltaic cells (e.g., as a p- or n-type material of the active layer of some photovoltaic cells, or as a dye to be employed in other photovoltaic cells); batteries, field-effect transistors; and light-emitting diodes.

Abstract: The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity.

Abstract: Process for the synthesis of the compound of formula (I): Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.

Abstract: This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a JAB1 blocker.

Abstract: The present invention relates to cyanoenamine derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions.

Abstract: Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

Abstract: This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.

Abstract: The present invention provides a dye compound of formula (I) or a salt thereof and a dye-sensitized solar cell using the dye compound: wherein R1 and R2 are, independently, H, C1-C12alkoxy or a halogen; and D1 and D2 are, independently, C1-C12alkyl, or D1, D2 and N form one of The dye compound is applicable to a dye-sensitized solar cell for increasing photoelectric efficiency of the dye-sensitized solar cell.

Abstract: The present disclosure relates to a sulfonated benzene compound emitting fluorescence by reaction with hydrogen peroxide, aqueous-dispersed fluorescent nanoprobes applicable for real-time detection of hydrogen peroxide, and a fluorescent nanoprobe fabrication method. The fluorescent nanoprobe contains the following sulfonated benzene compound and water.

Abstract: The present invention provides novel and advantageous processes for preparing and purifying pharmaceuticals The processes comprise a nucleophilic reaction wherein a modified leaving group LM, which has increased lipophilicity, of a vector in a nucleophilic reaction which offers a convenient and time-saving way to purify the product from non-reacted precursors vector-LM and by-products LM.

Abstract: The present invention relates to a dye compound represented by the following formula (I), or a salt thereof: wherein R1, R2, R3, R4, D1, D2, B, and n are defined the same as the specification, and also relates to a photoelectric component using the same. The dye compound of the present invention is suitable for Dye-Sensitized Solar Cell (DSSC). Hence, the photoelectric characteristics of the DSSC can be improved by using the dye compound of the present invention.

Abstract: A catalytic Wittig method utilizing a phosphine including the steps of providing a phosphine oxide precatalyst and reducing the phosphine oxide precatalyst to produce the phosphine; forming a phosphonium ylide precursor from the phosphine and a reactant; generating a phosphonium ylide from the phosphonium ylide precursor; reacting the phosphonium ylide precursor with the aldehyde, ketone, or ester to form the olefin and the phosphine oxide which then reenters the cycle. The invention is also directed to a Mitsunobu reaction catalytic in phosphine.

Abstract: The present invention provides a photosensitive resin composition for a color filter including a methine-based dye represented by the following Chemical Formula 1, and a color filter fabricated using the same. In Chemical Formula 1, R1 and R2 are respectively the same as defined in the specification.

Abstract: The present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection wherein the compound of formula (I) is a compound of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein A and B each represents a radical of formula and wherein —C-D- represents a bivalent radical of formula —N?CH—NR17—??(c-1); or —NR17—CH?N—??(c-2); provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).

Abstract: Cleavable compositions that comprise a polar head, cleavable linker, and a hydrophobic tail; and methods for using them to isolate hydrophobic molecules.

Abstract: New processes for manufacturing entacapone are provided.

Abstract: Compounds of the formula (I), wherein X is a single bond, CRaRbO, S, NRc or NCORc; Z is formula (II) or C3-C20heteroaryl; L, L1, L2, L3, L4, L5, L6, L7 and L8 for example independently of one another are hydrogen or an organic substituent; Ra, Rb and Rc independently of one another are hydrogen or an organic substituent; R is for example is C5-C20heteroaryl or C6-C14 aryl; and Y is an inorganic or organic anion; are suitable as photolatent acid generators.

Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.

Abstract: A process of preparing a radioactive compound containing a fluorine-18 isotope is provided. In one embodiment, the process may comprise forming a [18F] fluoroalkyl triflate by triflating a [18F] fluoroalkyl compound with AgOTf, and forming a [18F] fluoroalkylated radioactive compound through alkylation between the [18F] fluoroalkyl triflate and a radioactive compound precursor having at least one group selected from NH, OH and SH.

Abstract: This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions.

Abstract: Dyes for a dye-sensitized solar cell are provided. The dyes for a dye-sensitized solar cell have a structure of wherein each of X and Y independently comprises a substituent, comprising a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, and combinations thereof, and at least one of the X and Y comprises an aromatic group which are substituted a pyrene derivative substituted with an alkyl group or an aryl group, and Z comprises a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heterocyclic group, a vinyl group, and a substituted or unsubstituted polyvinyl group, and A comprises an acid functional group.

Abstract: A process for the preparation of entacapone, in particular as the polymorphic form A, comprising the preparation of a compound of formula (V), wherein R is C1-C6 alkyl, by condensation of N,N-diethyl-cyano-acetamide with a compound of formula (IV), wherein R is C1-C6 alkyl, in the presence of a strong basic agent; the dealkylation of the compound of formula (V) to obtain entacapone, and the crystallization thereof from methyl ethyl ketone is performed to yield the polymorphic form A. The polymorphic form A of entacapone may be used to treat Parkinson's disease and/or to enhance effectiveness of muscle control.

Abstract: The invention relates to an improved process for the manufacture of substituted 2-cyanocinnamic esters. This novel economical process provides products in high purity and yields.

Abstract: The present invention refers to new derivatives of the penta-1,4-dien-3-ones, as well as their processes of preparation. These compounds present strong antitumoral activity and promising antiparasitic action, behaving as almost atoxic by laboratory assays and also by hystopathologic studies. The present invention refers also to a pharmaceutical composition including the referred compounds, method of treatment for cancer and parasitic diseases.

Abstract: The present invention relates to a new method for obtaining Entacapone substantially free of Z-isomer from 3,4-dihydroxy-5-Nitrobenzaldehyde and N,N-Dimethylcyanoacetamide, or directly from a mixture of (E)- and (Z)-isomers of Entacapone, by formation of organic or inorganic salts, specially piperidine and sodium ones. A new crystalline form G of Entacapone can be obtained from this method in a fast, efficient, and simple way and substantially free of Z-isomer. Another object of the invention is a pharmaceutical composition comprising it.

Abstract: A branched ?-cyanostilbene fluorescent materials with a new structure useful to the organic electroluminescence display (OELD), which includes the organic substance in the state of powder, liquid and film with the stilbene core structure and the terminal branched phenyl structure. The fluorescent materials of the invention exhibits the high luminescent efficiency and is capable of tuning the fluorescent colors of red, green and blue according to the core structure in the molecular, i.e., the structure of stilbene radical, particularly it exhibits the higher luminescent efficiency in the state of solid more than solution.

Abstract: UV-absorbing polymers and copolymers suitable for Composition into sunscreens for the protection of human skin. The UV-absorbing chromophoric monomers chosen are simple and easily synthesized. With the correct choice of chromophoric monomer or mixture of monomers, protection against UV-A radiation or against both UV-A and UV-B radiation can be achieved. With the correct choice of comonomer, copolymers produced as aqueous latex emulsions or as Polyethylene Glycol solutions can also be achieved.

Abstract: Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a N-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof are provided, said processes comprise: a) reacting 4-(2-cyanoethenyl)-2,6-dimethylbenzenamine with an intermediate of formula (III) ?in the presence of a suitable solvent; b) reacting an intermediate of formula (IV) ?with acrylonitrile in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent; c) dehydrating the corresponding amide of the compound of formula (I).

Abstract: The present invention provides a holographic recording composition comprising a compound denoted by general formula (I) and a holographic recording medium comprising a recording layer, wherein the recording layer comprises a compound denoted by general formula (I). In general formula (I), R1 denotes a hydrogen atom or a substituent having a Hammett value, ?p, of equal to or greater than ?0.30, each of R2, R3, R4, R5, and R6 independently denotes a hydrogen atom or a substituent, each of A and B independently denotes a substituent and a combination of A and B is (cyano group, cyano group), (oxycarbonyl group, oxycarbonyl group), (acyl group, acyl group), (sulfonyl group, sulfonyl group), (cyano group, acyl group), (cyano group, sulfonyl group), (oxycarbonyl group, acyl group), (oxycarbonyl group, sulfonyl group), or (sulfonyl group, acyl group), and at least one of R1, R2, R3, R4, R5, R6, A, and B comprises a polymerizable group.

Abstract: A branched ?-cyanostilbene fluorescent materials with a new structure useful to the organic electroluminescence display (OELD), which includes the organic substance in the state of powder, liquid and film with the stilbene core structure and the terminal branched phenyl structure. The fluorescent materials of the invention exhibits the high luminescent efficiency and is capable of tuning the fluorescent colors of red, green and blue according to the core structure in the molecular, i.e., the structure of stilbene radical, particularly it exhibits the higher luminescent efficiency in the state of solid more than solution.

Abstract: Disclosed are 3-aryl-2-cyano-3-hydroxy-acrylic acid derivates of formula(1a) (1b) or (1c) wherein R1 is hydrogen, C1-C20alkyl; C1-C20alkoxy; CF3; C6-C10aryl; or a radical of formula (1a) and R2 is hydrogen; or C1-C20alkyl. The compounds are used as antimicrobial actives for the treatment of surfaces.

Abstract: A process to prepare (2E)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide (Entacapone) eliminating corrosive acids in the purification, with more than 99.5% purity with a Z-isomer content of less than 0.1% comprising condensation of e,4-Dihydroxy{5-nitrobensaldehyde with N,N-diethyl cyanoacetamide in the presence of a base selected from cyclic and acyclic secondary amines and a mixture of solvents, to obtain a crude product, stirring the crude product in a halogenated solvent, filtering and finally crystallization of polymorph A of Entacapone in a solvent.

Abstract: The invention disclosed in this application relates to an improved process for the preparation of Entacapone. In one embodiment the process involves: (i) reacting a 3-alkoxy-4-hydroxy-5-nitrobenzadehyde with N,N-diethylaminocyanoacetamide in the presence of a mild acid catalyst and a solvent, to provide a 3-O-alkylated Entacapone, and treating the 3-O-alkylated Entacapone with an acid catalyst in the presence of an organic base to provide Entacapone.

Abstract: The invention relates to three novel forms of entacapone. These are peripheral and selective COMT inhibitors which in combination with levodopa and decarboxylase inhibitors can be used to treating Parkinson's syndrome. Said novel forms arise by crystallization of entacapone in respectively determined conditions. In certain cases, entacapone can be used as a raw product, in a special case it can be used in situ as the product of Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide. Also disclosed are improvements of said condensation in relation to the catalyst and the production of the two components thereof.

Abstract: Liquid crystal polyester derived from phenylene-naphthalene monomers and one or more comonomers display an improved balance of properties, including low melt viscosity, fast cycle time in molding, very low mold shrinkage, high tensile and/or flexural strength, solvent resistance, excellent barrier properties, low water absorption, low thermal expansion coefficient, excellent thermostability, and/or low flammability. The phenylene-naphthalene monomers are The one or more comonomers include 4-hydroxybenzoic acid, 2-hydroxy-6-naphthoic acid, terephthalic acid, isophthalic acid, and derivatives and combinations thereof.

Abstract: Novel ultraviolet absorbing compounds that are liquid in nature, are low in color (and thus permit use without the concomitant necessity of adding large amounts of other coloring agents to combat such discoloring), and are highly effective in providing protection in wavelength ranges for which previous attempts at low-color ultraviolet absorbers have failed are provided herein. Such compounds provide such excellent, inexpensive, and beneficial protection from ultraviolet exposure within various media, including, but not limited to, clear thermoplastics. The particular compounds are generally polymeric in nature including various chain lengths of polyoxyalkylenes thereon and are liquid in nature to facilitate handling and introduction within the target media. In addition, such ultraviolet absorbers also exhibit extremely low migratory properties thereby providing long-term protective benefits to the target media as well.

Abstract: Compounds of Formula I: wherein R, R1 and R2 are each independently hydrogen or linear or branched C1 to C10 alkyl, or linear or branched C1 to C10 alkoxy; R3 is selected from the group consisting of COCH3, CO2R7, CONH2, CON(R8)2, CN, COX(CH2)n-N—(R4)(R5)(R6), and the quaternized salt form of the formula COX(CH2)n-N—(R4)(R5)(R6)+Y?; X is O or NH; n is an integer of 1 to 5; Y is an anion; R4, R5 and R6 are independently linear or branched C1 to C30 alkyl; and R7 and R8 are independently hydrogen or linear or branched C1-C30 alkyl. Sunscreen formulations containing compounds of Formula I, and methods for protecting hair, skin and substrates such as polymers, textiles, fabrics, leathers and paints using the compounds herein.

Abstract: Novel ultraviolet absorbing compounds that are liquid in nature, are extremely low in color (and thus permit use without the concomitant necessity of adding large amounts of other coloring agents to combat such discoloring), and are highly effective in providing protection in wavelength ranges for which previous attempts at low-color ultraviolet absorbers have failed are provided herein. Such compounds provide such excellent, inexpensive, and beneficial protection from ultraviolet exposure within various media, including, but not limited to, clear thermoplastics. The particular compounds are generally polymeric in nature including various chain lengths of polyoxyalkylenes thereon and are liquid in nature to facilitate handling and introduction within the target media. In addition, such ultraviolet absorbers also exhibit extremely low migratory properties thereby providing long-term protective benefits to the target media as well.

Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.

Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.

Abstract: Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor &agr;, nuclear factor &kgr;B, and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile.

Abstract: The acrylic acid esters of Formula I are useful for the delivery of organoleptic compounds, especially for flavors, fragrances, masking agents and antimicrobial compounds. They can also deliver fluorescent whitening agents.